Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
about
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerEvidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Pharmacologic resistance in colorectal cancer: a reviewExtending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization)Perspectives in the treatment of pancreatic adenocarcinomaEffectiveness and safety of s-1-based therapy compared with 5-Fluorouracil-based therapy for advanced colorectal cancer: a meta-analysisSecond-line systemic therapy for metastatic colorectal cancer.Oral drugs in the treatment of metastatic colorectal cancer.Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study.Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials.Colorectal cancer in Chinese patients: current and emerging treatment options.Efficacy of S-1 in colorectal cancer.S-1 in the treatment of pancreatic cancer.Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab vNew challenges and inspired answers for anticancer drug discovery and developmentDEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsA randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutProgression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancerReal-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapyIntegrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.Neoadjuvant chemotherapy followed by surgery versus surgery alone for colorectal cancer: meta-analysis of randomized controlled trials.Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerJapanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
P2860
Q24186145-94D8E83C-D069-4768-98B8-7034E62C3357Q24200737-738F383D-B95B-4635-B975-1B9A8E100AC0Q26752747-5550023F-757F-42D0-9090-821A92C0220CQ26769850-027C4E6D-F50A-4072-9A0B-6CBB9DE84059Q26796524-92CD6439-AC5D-44F4-8482-D2798CDF52A4Q26797248-7147811C-CC05-487E-BDCD-344C81EF4F6DQ27000790-132EAACD-0492-46EE-8833-2999EF00A4F2Q30238760-AA5426D0-3F23-422E-B74A-67ED226F6212Q30251387-17F381F5-1FBB-4892-812C-F15FF2491AD6Q33403083-8712C5DD-98C7-422A-B41B-A3EB33DCFC53Q33415971-155E3005-DA34-467C-BB2C-B8090D092C88Q33416158-3848C528-B6CC-48E5-B5E2-24FD7F4601F5Q33419175-31633E1C-06A1-4D3F-A4D6-378FED0F6DE6Q33423185-1662A56F-5C4D-4F6A-B006-18C224B30DA9Q33433227-C040F2B3-7540-4011-896C-0A741ACD0775Q33435747-4F62E032-3843-4A39-836D-D42B8F8840E3Q33436476-B50B32C4-8DD5-47CB-ABCB-4D31E40B1D50Q33439464-DED28F32-CA23-4C47-AFC5-7CC8C6304B29Q33710548-8519B6C5-D9BA-46D4-8D9A-F245FA85416CQ33820851-A2D7B128-8DA6-4A61-A78C-1C41B8364CFFQ34180260-06D1D917-0EC6-45B6-BA4D-0CF084CC53B9Q34352595-662A83AC-93D9-4CA4-AC4C-0F8C532B52C8Q34429445-CF59A846-3060-483F-B30D-8AB0012B41A4Q34467156-F1BCE718-3ABB-4B02-82F2-222AF7EE7F5EQ34547844-1785CBA8-C658-425C-B6EF-87C584FC55BAQ34981175-1CEF6BB4-9957-46C8-8AFF-9A51C861988FQ34991689-376AA361-7846-413F-8EAA-7CA43EF6E2A7Q35033392-71CD6DC6-FB07-4516-AED8-C173229C03C5Q35603648-F721A07A-B466-42A7-9401-82F4C852FDC0Q35624250-66160D90-2A5B-4C52-B465-49DB23C058C5Q35632548-11DADF06-DF6A-4A31-8C0F-2EB98C3E085AQ35756882-8728CFBE-F2EB-4008-BC69-83765843DC6EQ35768446-17DAA898-7CE1-4590-818B-5FA9368D544FQ35884411-280A3D45-9CE4-4019-96BD-C6356FDC84BAQ35940367-7618CFEB-75CD-44DA-AF8B-F5FD451C5C21Q36153879-443BD111-C693-4E36-B778-449089D45F42Q36300533-EFFE094B-DE04-44CD-9738-6D4CEBC6F915Q36324953-A4A31653-CE54-4B80-9388-4EB7951980B0Q36451754-6981DEED-3153-4377-8014-1D71A3BD4087Q36545367-830656EB-580F-4F72-8B07-9518B5287987
P2860
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Irinotecan plus S-1 (IRIS) ver ...... feriority study (FIRIS study).
@en
Irinotecan plus S-1
@nl
type
label
Irinotecan plus S-1 (IRIS) ver ...... feriority study (FIRIS study).
@en
Irinotecan plus S-1
@nl
prefLabel
Irinotecan plus S-1 (IRIS) ver ...... feriority study (FIRIS study).
@en
Irinotecan plus S-1
@nl
P2093
P1433
P1476
Irinotecan plus S-1 (IRIS) ver ...... feriority study (FIRIS study).
@en
P2093
Akihito Tsuji
Hideo Baba
Hiroya Takiuchi
Hiroyuki Kuwano
Ichinosuke Hyodo
Kenichi Sugihara
Kensei Yamaguchi
Masahiko Watanabe
P304
P356
10.1016/S1470-2045(10)70181-9
P577
2010-08-12T00:00:00Z